The store will not work correctly when cookies are disabled.
N4-(2-chlorobenzyl)-N2-methyl-6-(pyridin-2-yl)pyrimidine-2,4-diamine
ID: ALA5207240
PubChem CID: 124277855
Max Phase: Preclinical
Molecular Formula: C17H16ClN5
Molecular Weight: 325.80
Associated Items:
Names and Identifiers
Canonical SMILES: CNc1nc(NCc2ccccc2Cl)cc(-c2ccccn2)n1
Standard InChI: InChI=1S/C17H16ClN5/c1-19-17-22-15(14-8-4-5-9-20-14)10-16(23-17)21-11-12-6-2-3-7-13(12)18/h2-10H,11H2,1H3,(H2,19,21,22,23)
Standard InChI Key: QICGQVSBLJCONR-UHFFFAOYSA-N
Molfile:
RDKit 2D
23 25 0 0 0 0 0 0 0 0999 V2000
-1.0741 2.8901 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3595 3.3024 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.3523 2.8904 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.3523 2.0653 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.3577 1.6535 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0741 2.0616 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3577 0.8283 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.3567 0.4155 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.3560 -0.4071 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3587 -0.8199 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-1.0707 -0.4107 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0754 0.4139 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.0706 -0.8197 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.7853 -0.4071 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.7853 -0.8233 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-1.7853 -1.6484 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0707 -2.0611 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3558 -1.6486 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.3562 -2.0607 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.3562 -2.8861 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3541 -3.2980 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0707 -2.8898 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.7853 -3.3024 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 0
3 2 1 0
4 3 2 0
5 4 1 0
1 6 1 0
6 5 2 0
5 7 1 0
8 7 2 0
9 8 1 0
10 9 2 0
11 10 1 0
12 11 2 0
7 12 1 0
9 13 1 0
13 14 1 0
11 15 1 0
15 16 1 0
16 17 1 0
18 17 2 0
19 18 1 0
20 19 2 0
21 20 1 0
22 21 2 0
17 22 1 0
22 23 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 325.80 | Molecular Weight (Monoisotopic): 325.1094 | AlogP: 3.85 | #Rotatable Bonds: 5 |
Polar Surface Area: 62.73 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
#RO5 Violations: ┄ | HBA (Lipinski): 5 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: ┄ | CX Basic pKa: 5.43 | CX LogP: 3.80 | CX LogD: 3.79 |
Aromatic Rings: 3 | Heavy Atoms: 23 | QED Weighted: 0.75 | Np Likeness Score: -1.67 |
References
1. Burley R, Hewer RC, Teall M, Dickson L, Ossola B, Russell S, Bender C, Cheung T, Powell JAC, Xu X, Brice NL, Otter L, Arimont M, Kidd SL, Vidal D, Dale JW, Mervin L, Sore HF, Mateu N, Lakshminarayana N, Dawson LA, Carlton M, Bürli RW.. (2022) Synthesis and SAR of novel GPR39 agonists and positive allosteric modulators., 61 [PMID:35123006] [10.1016/j.bmcl.2022.128607] |